(AOF) – Integragen announced an unaudited turnover of 11.75 million euros in 2023, down 7% compared to 2022. This company specializing in the decryption of the human genome explains this drop in revenue ” mainly by the drop in activities linked to Covid-19″, “partially offset by a significant increase in revenue linked to other sectors of activity”. The company’s cash position as of December 31, 2023 amounts to €2.9 million, in line with the company’s expectations and the 2023 budget
While the SeqOIA platform experienced growth of 9%, activities related to microbiology with the P2M platform of the Pasteur Institute, closely linked to the Covid-19 pandemic, decreased by 37%.
As the 5-year contract with GCS SeqOIA ends on February 29, 2024, IntegraGen has implemented a right-sizing effort to support improved profitability, resulting in a “significant” reduction in its total workforce beginning in February 2024.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.